992 related articles for article (PubMed ID: 23677868)
21. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
22. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
23. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
24. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12).
Ishida-Kitagawa N; Tanaka K; Bao X; Kimura T; Miura T; Kitaoka Y; Hayashi K; Sato M; Maruoka M; Ogawa T; Miyoshi J; Takeya T
J Biol Chem; 2012 May; 287(21):17493-17502. PubMed ID: 22451653
[TBL] [Abstract][Full Text] [Related]
25. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
26. Lymphocytes and the Dap12 adaptor are key regulators of osteoclast activation associated with gonadal failure.
Anginot A; Dacquin R; Mazzorana M; Jurdic P
PLoS One; 2007 Jul; 2(7):e585. PubMed ID: 17611620
[TBL] [Abstract][Full Text] [Related]
27. High dose M-CSF partially rescues the Dap12-/- osteoclast phenotype.
Faccio R; Zou W; Colaianni G; Teitelbaum SL; Ross FP
J Cell Biochem; 2003 Dec; 90(5):871-83. PubMed ID: 14624447
[TBL] [Abstract][Full Text] [Related]
28. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
[TBL] [Abstract][Full Text] [Related]
31. Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.
Li S; Yang B; Teguh D; Zhou L; Xu J; Rong L
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735865
[TBL] [Abstract][Full Text] [Related]
32. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase.
Mócsai A; Humphrey MB; Van Ziffle JA; Hu Y; Burghardt A; Spusta SC; Majumdar S; Lanier LL; Lowell CA; Nakamura MC
Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6158-63. PubMed ID: 15073337
[TBL] [Abstract][Full Text] [Related]
33. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
34. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic insight into osteoclast differentiation in osteoimmunology.
Takayanagi H
J Mol Med (Berl); 2005 Mar; 83(3):170-9. PubMed ID: 15776286
[TBL] [Abstract][Full Text] [Related]
36. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
37. TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways.
Cicek M; Vrabel A; Sturchio C; Pederson L; Hawse JR; Subramaniam M; Spelsberg TC; Oursler MJ
PLoS One; 2011 Mar; 6(3):e17522. PubMed ID: 21423731
[TBL] [Abstract][Full Text] [Related]
38. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
[TBL] [Abstract][Full Text] [Related]
39. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
40. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
